✦ LIBER ✦

Phase II trial of the multi-targeted antifolate LY231514 (MTA) as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC)

✍ Scribed by Rusthoven, J.; Eisenhauer, E.; Butts, C.; Gregg, R.; Dancey, J.; Fisher, B.; Iglesias, J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

768 - Phase II study of a multi-targeted

✍ M.C. Cripps; M. Bumell; J. Jolivet; W. Lofters; B. Fisher; L. Panasci; J. Igiesi 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 263 KB

Phase II trial of mta (LY231514) in pati

✍ P. Postmus; K. Mattson; von Pawel; C. Manegold; E. Smit; M. Millward; S. Clarke; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 183 KB

Phase II trial of MTA (AlimtaTM) and cis

✍ Shepherd, F.A; Arnold, A; Neville, A; Dancey, J; Rusthoven, J; Fisher, B; Eisenh 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 113 KB

Phase II trial of gemcitabine as second

✍ Gillenwater, HH; Tynan, M; Socinski, MA 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 129 KB

Phase II trial of weekly docetaxel and g

✍ Sujith Kalmadi; Giles McNeill; Mellar Davis; David Peereboom; David Adelstein; T 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 68 KB

Weekly docetaxel as first-line therapy f

✍ Hainsworth, J.D; Burris, H.A; Morrissey, L.H; Litchy, S; Greco, F.A 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 96 KB